No data available for drug.
DRUG INTERACTION
No drug interaction found for candesartan cilexetil and .
perindopril
may have an increasingly adverse effect when combined with angiotensin-converting enzyme inhibitors
quinapril
may have an increasingly adverse effect when combined with angiotensin-converting enzyme inhibitors
ramipril
may have an increasingly adverse effect when combined with angiotensin-converting enzyme inhibitors
rescinnamine
may have an increasingly adverse effect when combined with angiotensin-converting enzyme inhibitors
spirapril
may have an increasingly adverse effect when combined with angiotensin-converting enzyme inhibitors
benazepril
may have an increasingly adverse effect when combined with angiotensin-converting enzyme inhibitors
captopril
may have an increasingly adverse effect when combined with angiotensin-converting enzyme inhibitors
cilazapril
may have an increasingly adverse effect when combined with angiotensin-converting enzyme inhibitors
enalapril
may have an increasingly adverse effect when combined with angiotensin-converting enzyme inhibitors
enalaprilat
may have an increasingly adverse effect when combined with angiotensin-converting enzyme inhibitors
aliskiren
may increase the hyperkalemic effect of aliskiren
lithium carbonate
may enhance the serum concentration of angiotensin II receptor blockers
aliskiren
may increase the hyperkalemic effect of aliskiren
ramipril
it may either increases toxicity of the other by pharmacodynamic synergism
sparsentan
it increases the toxicity of angiotensin II receptor blockers
diphenhydramine/ibuprofen
angiotensin II Receptor Blockers may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents
meclofenamate
angiotensin II Receptor Blockers may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents
aspirin
angiotensin II Receptor Blockers may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents
bumadizone
angiotensin II Receptor Blockers may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents
nabumetone
angiotensin II Receptor Blockers may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents
glycol salicylate
may diminish the therapeutic effect of angiotensin II Receptor Blockers
tiaprofenic acid
may diminish the therapeutic effect of angiotensin II Receptor Blockers
tanshinone I
may enhance the risk of adverse/toxic effect of NSAIDs
caryophyllene
may enhance the risk of adverse/toxic effect of NSAIDs
ursolic acid
may enhance the risk of adverse/toxic effect of NSAIDs
cepharanthine
may enhance the risk of adverse/toxic effect of NSAIDs
maitake
It may enhance the effects when combined with maitake by pharmacodynamic synergism
amiloride
Angiotensin II Receptor Blockers: they may increase the hyperkalemic effect of potassium-sparing diuretics
canrenoic acid
Angiotensin II Receptor Blockers: they may increase the hyperkalemic effect of potassium-sparing diuretics
eplerenone
Angiotensin II Receptor Blockers: they may increase the hyperkalemic effect of potassium-sparing diuretics
amiloride
angiotensin II Receptor Blockers may enhance the hyperkalemic effect of potassium-Sparing Diuretics
eplerenone
angiotensin II Receptor Blockers may enhance the hyperkalemic effect of potassium-Sparing Diuretics
finerenone (Rx)
angiotensin II Receptor Blockers may enhance the hyperkalemic effect of finerenone
heparin
it increases the effect of hyperkalemia of angiotensin II receptor blockers
ethacrynic acid
it increases the hypotensive effect of angiotensin II receptor blockers
bumetanide
it increases the hypotensive effect of angiotensin II receptor blockers
muzolimine
it increases the hypotensive effect of angiotensin II receptor blockers
tanshinone I
angiotensin II receptor blockers increase the toxicity of NSAIDs
rosmarinic acid
angiotensin II receptor blockers increase the toxicity of NSAIDs
caryophyllene
angiotensin II receptor blockers increase the toxicity of NSAIDs
ursolic acid
angiotensin II receptor blockers increase the toxicity of NSAIDs
cepharanthine
angiotensin II receptor blockers increase the toxicity of NSAIDs
ranolazine
it increases the toxicity of angiotensin II receptor blockers
zofenopril
ACE Inhibitors may enhance the therapeutic effect of angiotensin II receptor antagonists
benazepril
ACE Inhibitors may enhance the therapeutic effect of angiotensin II receptor antagonists
captopril
ACE Inhibitors may enhance the therapeutic effect of angiotensin II receptor antagonists
cilazapril
ACE Inhibitors may enhance the therapeutic effect of angiotensin II receptor antagonists
enalapril
ACE Inhibitors may enhance the therapeutic effect of angiotensin II receptor antagonists
ethacrynic acid
may enhance the hypotensive effect of angiotensin II receptor antagonist
bumetanide
may enhance the hypotensive effect of angiotensin II receptor antagonist
muzolimine
may enhance the hypotensive effect of angiotensin II receptor antagonist
dapoxetine
may increase the orthostatic hypotensive effect of dapoxetine
mefenamic acid
may increase the toxic effect of nonsteroidal anti-inflammatory agents
tolvaptan
may increase the hyperkalemic effect when combined with angiotensin II receptor blockers
heparin
may have an increased hyperkalemic effect when combined with angiotensin ii receptor blockers
eplerenone
eplerenone: they may increase the hyperkalemic effect of Angiotensin II Receptor antagonist
finerenone (Rx)
finerenone: they may increase the hyperkalemic effect of Angiotensin II Receptor Blockers
heparin
heparins: they may increase the hyperkalemic effect of Angiotensin II Receptor Blockers
enoxaparin
heparins: they may increase the hyperkalemic effect of Angiotensin II Receptor Blockers
selexipag
heparins: they may increase the hyperkalemic effect of Angiotensin II Receptor Blockers
nicorandil
nicorandil: they may increase the hyperkalemic effect of Angiotensin II Receptor Blockers
ranolazine
ranolazine: they may increase the toxic effect of Angiotensin II Receptor Blockers
tacrolimus
tacrolimus: they may increase the hyperkalemic effect of Angiotensin II Receptor Blockers
trimethoprim
trimethoprim: they may increase the hyperkalemic effect of Angiotensin II Receptor Blockers
tolvaptan
may enhance the hyperkalemic effect
famprofazone
they decrease the effect of hypertension of angiotensin II
quinapril
may have an increased therapeutic effect when combined with angiotensin II receptor blocker
ramipril
may have an increased therapeutic effect when combined with angiotensin II receptor blocker
rescinnamine
may have an increased therapeutic effect when combined with angiotensin II receptor blocker
spirapril
may have an increased therapeutic effect when combined with angiotensin II receptor blocker
enalaprilat
angiotensin II receptor blockers increase the toxicity of ACE inhibitors
lisinopril
angiotensin II receptor blockers increase the toxicity of ACE inhibitors
perindopril
angiotensin II receptor blockers increase the toxicity of ACE inhibitors
No data available for drug.
DRUG INTERACTION
candesartan cilexetil
&
No Drug Intearction Found. for candesartan cilexetil and .
perindopril
may have an increasingly adverse effect when combined with angiotensin-converting enzyme inhibitors
quinapril
may have an increasingly adverse effect when combined with angiotensin-converting enzyme inhibitors
ramipril
may have an increasingly adverse effect when combined with angiotensin-converting enzyme inhibitors
rescinnamine
may have an increasingly adverse effect when combined with angiotensin-converting enzyme inhibitors
spirapril
may have an increasingly adverse effect when combined with angiotensin-converting enzyme inhibitors
benazepril
may have an increasingly adverse effect when combined with angiotensin-converting enzyme inhibitors
captopril
may have an increasingly adverse effect when combined with angiotensin-converting enzyme inhibitors
cilazapril
may have an increasingly adverse effect when combined with angiotensin-converting enzyme inhibitors
enalapril
may have an increasingly adverse effect when combined with angiotensin-converting enzyme inhibitors
enalaprilat
may have an increasingly adverse effect when combined with angiotensin-converting enzyme inhibitors
aliskiren
may increase the hyperkalemic effect of aliskiren
lithium carbonate
may enhance the serum concentration of angiotensin II receptor blockers
aliskiren
may increase the hyperkalemic effect of aliskiren
ramipril
it may either increases toxicity of the other by pharmacodynamic synergism
sparsentan
it increases the toxicity of angiotensin II receptor blockers
diphenhydramine/ibuprofen
angiotensin II Receptor Blockers may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents
meclofenamate
angiotensin II Receptor Blockers may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents
aspirin
angiotensin II Receptor Blockers may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents
bumadizone
angiotensin II Receptor Blockers may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents
nabumetone
angiotensin II Receptor Blockers may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents
glycol salicylate
may diminish the therapeutic effect of angiotensin II Receptor Blockers
tiaprofenic acid
may diminish the therapeutic effect of angiotensin II Receptor Blockers
tanshinone I
may enhance the risk of adverse/toxic effect of NSAIDs
caryophyllene
may enhance the risk of adverse/toxic effect of NSAIDs
ursolic acid
may enhance the risk of adverse/toxic effect of NSAIDs
cepharanthine
may enhance the risk of adverse/toxic effect of NSAIDs
maitake
It may enhance the effects when combined with maitake by pharmacodynamic synergism
amiloride
Angiotensin II Receptor Blockers: they may increase the hyperkalemic effect of potassium-sparing diuretics
canrenoic acid
Angiotensin II Receptor Blockers: they may increase the hyperkalemic effect of potassium-sparing diuretics
eplerenone
Angiotensin II Receptor Blockers: they may increase the hyperkalemic effect of potassium-sparing diuretics
amiloride
angiotensin II Receptor Blockers may enhance the hyperkalemic effect of potassium-Sparing Diuretics
eplerenone
angiotensin II Receptor Blockers may enhance the hyperkalemic effect of potassium-Sparing Diuretics
finerenone (Rx)
angiotensin II Receptor Blockers may enhance the hyperkalemic effect of finerenone
heparin
it increases the effect of hyperkalemia of angiotensin II receptor blockers
ethacrynic acid
it increases the hypotensive effect of angiotensin II receptor blockers
bumetanide
it increases the hypotensive effect of angiotensin II receptor blockers
muzolimine
it increases the hypotensive effect of angiotensin II receptor blockers
tanshinone I
angiotensin II receptor blockers increase the toxicity of NSAIDs
rosmarinic acid
angiotensin II receptor blockers increase the toxicity of NSAIDs
caryophyllene
angiotensin II receptor blockers increase the toxicity of NSAIDs
ursolic acid
angiotensin II receptor blockers increase the toxicity of NSAIDs
cepharanthine
angiotensin II receptor blockers increase the toxicity of NSAIDs
ranolazine
it increases the toxicity of angiotensin II receptor blockers
zofenopril
ACE Inhibitors may enhance the therapeutic effect of angiotensin II receptor antagonists
benazepril
ACE Inhibitors may enhance the therapeutic effect of angiotensin II receptor antagonists
captopril
ACE Inhibitors may enhance the therapeutic effect of angiotensin II receptor antagonists
cilazapril
ACE Inhibitors may enhance the therapeutic effect of angiotensin II receptor antagonists
enalapril
ACE Inhibitors may enhance the therapeutic effect of angiotensin II receptor antagonists
ethacrynic acid
may enhance the hypotensive effect of angiotensin II receptor antagonist
bumetanide
may enhance the hypotensive effect of angiotensin II receptor antagonist
muzolimine
may enhance the hypotensive effect of angiotensin II receptor antagonist
dapoxetine
may increase the orthostatic hypotensive effect of dapoxetine
mefenamic acid
may increase the toxic effect of nonsteroidal anti-inflammatory agents
tolvaptan
may increase the hyperkalemic effect when combined with angiotensin II receptor blockers
heparin
may have an increased hyperkalemic effect when combined with angiotensin ii receptor blockers
eplerenone
eplerenone: they may increase the hyperkalemic effect of Angiotensin II Receptor antagonist
finerenone (Rx)
finerenone: they may increase the hyperkalemic effect of Angiotensin II Receptor Blockers
heparin
heparins: they may increase the hyperkalemic effect of Angiotensin II Receptor Blockers
enoxaparin
heparins: they may increase the hyperkalemic effect of Angiotensin II Receptor Blockers
selexipag
heparins: they may increase the hyperkalemic effect of Angiotensin II Receptor Blockers
nicorandil
nicorandil: they may increase the hyperkalemic effect of Angiotensin II Receptor Blockers
ranolazine
ranolazine: they may increase the toxic effect of Angiotensin II Receptor Blockers
tacrolimus
tacrolimus: they may increase the hyperkalemic effect of Angiotensin II Receptor Blockers
trimethoprim
trimethoprim: they may increase the hyperkalemic effect of Angiotensin II Receptor Blockers
tolvaptan
may enhance the hyperkalemic effect
famprofazone
they decrease the effect of hypertension of angiotensin II
quinapril
may have an increased therapeutic effect when combined with angiotensin II receptor blocker
ramipril
may have an increased therapeutic effect when combined with angiotensin II receptor blocker
rescinnamine
may have an increased therapeutic effect when combined with angiotensin II receptor blocker
spirapril
may have an increased therapeutic effect when combined with angiotensin II receptor blocker
enalaprilat
angiotensin II receptor blockers increase the toxicity of ACE inhibitors
lisinopril
angiotensin II receptor blockers increase the toxicity of ACE inhibitors
perindopril
angiotensin II receptor blockers increase the toxicity of ACE inhibitors
medtigo
Action and Spectrum
Drug Interaction
Adverse Reaction
Black Box Warning
Contraindication / Caution
Pregnancy / Lactation
Pharmacology
Adminstartion
Patient Information Leaflet